Nordic nanovector_PhII_CD37_mAb_radionuclide_FL (Non-Hodgkin Lymphoma)
What is the Purpose of this Study?
Who Can Participate in this Study?
-Have relapsed Follicular Lymphoma and have received 2 or more chemotherapy or immunotherapy based regimens.
What is Involved?
If you choose to be in this study:
-You will be randomly assigned (like flipping a coin) to get either dose A or does B of the study drug Betalutin. The only difference in the groups is the amount of the study drug given.
-Receive one single dose of study drug as an injection into a vein
-Give a small blood sample once a week for 12 weeks
-Follow-up visits 3 to 6 months for up to 5 years
-CT/PET scans at some follow-up visits
conjugate for treatment of relapsed non-Hodgkin lymphoma.